Clinical Trial Update: Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating vaccine therapy with interleukin-12 after surgery in melanoma patients, using either alum (aluminum hydroxide) or sar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intraocular Melanoma
• Melanoma

Drugs mentioned

• Interleukin-12 (interleukin-12)
• alum (aluminum hydroxide) (aluminum hydroxide)
• sargramostim (sargramostim)

Snippet

Sponsor: University of Southern California | Conditions: Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Status: COMPLETED